Sign In  |  Register  |  About San Rafael  |  Contact Us

San Rafael, CA
September 01, 2020 1:37pm
7-Day Forecast | Traffic
  • Search Hotels in San Rafael

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

QT Imaging’s Breast Acoustic CT™ Scanner Used in Study for Early Identification of Response of Breast Cancer Patients to Neoadjuvant Chemotherapy

QT Imaging Holdings, Inc. (NASDAQ:QTI) a medical device company engaged in research, development, and commercialization of innovative body imaging systems, is pleased to announce the delivery of a Breast Acoustic CT™ Scanner under a unique collaboration with the Department of Radiation Oncology, and Radiation Treatment Program at the Sunnybrook Health Sciences Centre in Toronto, Canada, one of the largest cancer centers in Canada, and The University of Illinois, Urbana-Champaign, Department of Electrical and Computer Engineering and Grainger College of Engineering. This collaboration is part of a five-year research grant from National Institutes of Health/National Cancer Institute to develop an inexpensive, portable, safe, and repeatable imaging approach capable of accurate and early identification of response of breast cancer patients to neoadjuvant chemotherapy (NAC).

As part of this grant, Breast Acoustic CT™ (ACT) quantitative images with independent biomarkers known to be sensitive to cancer will be collected, and the response of cancer to therapy, will be derived from quantitative ultrasound based on backscatter analysis. The successful results of this collaboration will yield additional quantitative markers (radiomics) with improved estimate precision not afforded by conventional ultrasound scanners.

This collaboration also addresses the ongoing clinical need in breast cancer therapy for the development of an inexpensive, robust, and accurate technique to identify the response, within weeks, of breast cancer to neoadjuvant chemotherapy. The early identification of non-responders to NAC or any cancer treatment remains a highly significant medical problem and necessary for adaptive precision medicine.

"The QTI Breast Acoustic CT™ System represents the future of tomographic imaging, offering quantitatively accurate, 3D, high resolution breast images, taken with no safety or discomfort for women," said James Wiskin, PhD, Principal Scientist and QTI Fellow. "The ACT system is especially appropriate for dense breasts and young women with risk factors. This partnership serves as a testament to collaborations between leaders in industry and academia."

"Unfortunately, not all therapies work in cancer patients and the ability to determine which are effective and which treatments are ineffective in days instead of months is very important. With the QTI Breast Acoustic CT™ System we plan to implement quantitative ultrasound methods which can be used for exactly that kind of determination to enable personalized care," stated Greg Czarnota, MD, PhD, Clinician Scientist Department of Radiation Oncology at Sunnybrook Health Sciences Centre in Toronto, Canada.

About QT Imaging Holdings, Inc.

QT Imaging Holdings, Inc. is a public (NASDAQ: QTI) medical device company engaged in research, development, and commercialization of innovative body imaging systems using low frequency sound waves. QT Imaging Holdings, Inc. strives to improve global health outcomes. Its strategy is predicated upon the fact that medical imaging is critical to the detection, diagnosis, and treatment of disease and that it should be safe, affordable, accessible, and centered on the patient’s experience. For more information on QT Imaging Holdings, Inc., please visit the company’s website at www.qtimaging.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements contain words such as “will,” and “expect,” or the negative thereof or comparable terminology, and include (without limitation) statements regarding the QTI Breast Acoustic CT™ System and its use in the research collaboration and images that may be rendered as part of this research, plans for QT Imaging Holdings, new product development and introduction, and product sales growth and projected revenues. Forward-looking statements involve certain risks and uncertainties, and actual results may differ materially from those discussed in any such statement. These risks include, but are not limited to: the ability of the parties to sell and deploy the QTI Breast Acoustic CT™ System, the ability to extend product offerings into new areas or products, the ability to commercialize technology, unexpected occurrences that deter the full documentation and “bring to market” plan for products, trends and fluctuations in the industry, changes in demand and purchasing volume of customers, unpredictability of suppliers, the ability to attract and retain qualified personnel and the ability to move product sales to production levels. Additional factors that could cause actual results to differ are discussed under the heading “Risk Factors” and in other sections of QT Imaging’s (and its predecessor, GigCapital5, Inc.) filings with the SEC, and in its other current and periodic reports filed or furnished from time to time with the SEC. All forward-looking statements in this press release are made as of the date hereof, based on information available to QT Imaging Holdings as of the date hereof, and QT Imaging Holdings assumes no obligation to update any forward-looking statement.

Contacts

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 SanRafael.com & California Media Partners, LLC. All rights reserved.